We report two cases of flutamide-induced hepatotoxicity in
patients treated with the drug for metastatic prostatic carcinoma.
In both patients the latency period between drug
intake and onset of symptoms, (80-150 days) the history,
the type of the reaction and the histological findings were
compatible with the diagnosis of drug-induced hepatotoxicity.
In addition, other causes of hepatobiliary disorders
were excluded and in the first case the diagnosis was confirmed
by a rechallenge. It is concluded that patients receiving
flutamide should be carefully monitored with liver
function tests and the drug should be promptly discontinued
if liver toxicity is detected.
Key words: flutamide, hepatitis, cholestasis, rechallenge